Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2004

Zhang Zhuo, Wang Hui, Prasad Gautam, Li Mao, Yu Dong, Bonner James A, Agrawal Sudhir, Zhang Ruiwen

Abstract excerpt

PURPOSE: The MDM2 oncogene, amplified or overexpressed in many human cancers, has been suggested to be a novel target for cancer therapy. We have demonstrated a second-generation antisense antihuman-MDM2 oligonucleotide to have antitumor activity when administered alone or in combination with can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to Dose-Response Relationship, Radiation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to E2F Transcription Factors

Share to E2F1 Transcription Factor

Share to Gamma Rays

Share to Oligonucleotides, Antisense

Share to Proto-Oncogene Proteins c-mdm2

Share to Radiotherapy

Source

Identifiers

PMID: 14977824
DOI: 10.1158/1078-0432.ccr-0245-03

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14977824-2026-09-02.1. Manifest publication-graph-cohort-2026-09-02.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.PMID 14977824Read ↗

Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and MechanismsSemantic proximity Read ↗

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapySemantic proximity Read ↗

Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.Semantic proximity Read ↗

MDM2 oncogene as a target for cancer therapy: An antisense approach.Semantic proximity Read ↗

Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent MechanismsSemantic proximity Read ↗

MDM2 Oncogene as a Novel Target for Human Cancer TherapySemantic proximity Read ↗

Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression.Semantic proximity Read ↗

MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted TherapySemantic proximity Read ↗

Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells.Semantic proximity Read ↗

Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.Semantic proximity Read ↗

Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53‐independent pancreatic cancer cell deathSemantic proximity Read ↗

Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.